10 Stocks Left Behind Amid Wall Street Cheer

2. Soleno Therapeutics Inc. (NASDAQ:SLNO)

Soleno Therapeutics extended its losing streak to a 5th consecutive day on Wednesday, slashing 26.59 percent to close at $46.87 apiece as investors appeared to have priced in a strong earnings performance in the third quarter of the year.

The maker of the first and only FDA-approved drug for hyperphagia said in an updated report that it swung to a net income of $26 million, or a 134 percent improvement from the $76.6 million net loss in the same period last year. It also incurred revenues of $66 million during the quarter.

“Our strong third quarter results reflect growing awareness of the compelling efficacy and safety profile of Vykat XR within the PWS community,” said Soleno Therapeutics Inc. (NASDAQ:SLNO) Chairman and CEO Anish Bhatnagar.

“As the first and only FDA-approved therapy to treat the hallmark symptom of PWS—hyperphagia—in patients 4 years and older, Vykat XR can offer a new option to this fragile and complex patient population that often suffers from a multitude of serious co-morbidities … and we are working tirelessly to make it as broadly accessible as possible,” he added.